Varicella-zoster virus-specific antibody responses in 50-59-year-old recipients of zoster vaccine.

TitleVaricella-zoster virus-specific antibody responses in 50-59-year-old recipients of zoster vaccine.
Publication TypeJournal Article
Year of Publication2013
AuthorsLevin MJ, Schmader KE, Gnann JW, McNeil SA, Vesikari T, Betts RF, Keay S, Stek JE, Bundick ND, Su S-C, Zhao Y, Li X, Chan ISF, Annunziato PW, Parrino J
JournalThe Journal of infectious diseases
Volume208
Issue9
Pagination1386-90
Date Published2013 Nov 1
Abstract

Prevaccination and 6-week postvaccination samples from the immunogenicity substudy (n = 2269) of the zoster vaccine (ZV) efficacy trial (N = 22 439) in 50-59-year-old subjects were examined for varicella-zoster virus-specific antibody responses to vaccination. The varicella-zoster virus geometric mean titer (GMT) and geometric mean fold rise were higher in ZV recipients than in placebo recipients (GMT, 660.0 vs 293.1 glycoprotein enzyme-linked immunosorbent assay units/mL [P < .001], respectively; geometric mean fold rise, 2.31 vs 1.00 [P < .025]). In each group there was a strong inverse correlation between postvaccination GMT and risk of subsequent herpes zoster. Although these data provide strong evidence that relates ZV-induced antibody and the risk of herpes zoster, a protective threshold was not determined. Clinical Trials Registration. NCT00534248.

DOI10.7861/clinmedicine.13-4-374
Alternate JournalJ. Infect. Dis.